REG - IXICO plc - Notice of Results

IXICOAnnouncement

22/11/2019 07:05

RNS Number : 2848U
IXICO plc
22 November 2019
 


 22 November 2019
IXICO plc
("IXICO" or the "Company")
 
Notice of Results
 
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on Wednesday, 4 December 2019.
 
Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 GMT on the day of the results.  Further details will be provided on request.
 
For further information please contact:
 



IXICO plc


+44 (0) 20 3763 7498




Giulio Cerroni, Chief Executive Officer


















Cenkos Securities PLC (Nominated adviser and sole broker)


+44 (0) 20 7397 8900




Giles Balleny / Max Gould (Corporate Finance)








Michael F Johnson / Russell Kerr (Sales)


















Optimum Strategic Communications


 +44 (0) 203 950 9144




Mary Clark / Supriya Mathur / Manel Mateus








ixico@optimumcomms.com







 
About IXICO
 
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease. 
 
Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
 
More information is available on www.IXICO.com
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBRBDBUSDBGCB